Becton Dickinson Research and Development Expenses 2010-2025 | BDX

Becton Dickinson annual/quarterly research and development expenses history and growth rate from 2010 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Becton Dickinson research and development expenses for the quarter ending March 31, 2025 were $302M, a 1% increase year-over-year.
  • Becton Dickinson research and development expenses for the twelve months ending March 31, 2025 were $1.246B, a 5.95% increase year-over-year.
  • Becton Dickinson annual research and development expenses for 2024 were $1.19B, a 3.8% decline from 2023.
  • Becton Dickinson annual research and development expenses for 2023 were $1.237B, a 1.51% decline from 2022.
  • Becton Dickinson annual research and development expenses for 2022 were $1.256B, a 1.8% decline from 2021.
Becton Dickinson Annual Research and Development Expenses
(Millions of US $)
2024 $1,190
2023 $1,237
2022 $1,256
2021 $1,279
2020 $1,039
2019 $1,062
2018 $1,004
2017 $770
2016 $828
2015 $632
2014 $550
2013 $494
2012 $472
2011 $470
2010 $423
2009 $405
Becton Dickinson Quarterly Research and Development Expenses
(Millions of US $)
2025-03-31 $302
2024-12-31 $343
2024-09-30 $302
2024-06-30 $299
2024-03-31 $299
2023-12-31 $290
2023-09-30 $281
2023-06-30 $306
2023-03-31 $337
2022-12-31 $313
2022-09-30 $300
2022-06-30 $315
2022-03-31 $327
2021-12-31 $314
2021-09-30 $341
2021-06-30 $330
2021-03-31 $317
2020-12-31 $291
2020-09-30 $243
2020-06-30 $262
2020-03-31 $264
2019-12-31 $270
2019-09-30 $270
2019-06-30 $282
2019-03-31 $252
2018-12-31 $258
2018-09-30 $277
2018-06-30 $277
2018-03-31 $259
2017-12-31 $191
2017-09-30 $215
2017-06-30 $186
2017-03-31 $187
2016-12-31 $182
2016-09-30 $252
2016-06-30 $207
2016-03-31 $182
2015-12-31 $187
2015-09-30 $196
2015-06-30 $178
2015-03-31 $129
2014-12-31 $129
2014-09-30 $140
2014-06-30 $137
2014-03-31 $147
2013-12-31 $126
2013-09-30 $133
2013-06-30 $121
2013-03-31 $122
2012-12-31 $118
2012-09-30 $128
2012-06-30 $115
2012-03-31 $117
2011-12-31 $112
2011-09-30 $121
2011-06-30 $114
2011-03-31 $119
2010-12-31 $116
2010-09-30 $115
2010-06-30 $108
2010-03-31 $100
2009-12-31 $99
2009-09-30 $110
2009-06-30 $98
2009-03-31 $99
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $51.260B $20.178B
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $88.805B 21.44
Cardinal Health (CAH) United States $38.083B 19.94
Straumann Holding AG (SAUHY) Switzerland $20.857B 0.00
West Pharmaceutical Services (WST) United States $15.151B 31.76
Cooper (COO) United States $14.525B 18.72
Align Technology (ALGN) United States $13.828B 27.45
Henry Schein (HSIC) United States $8.411B 14.43
Merit Medical Systems (MMSI) United States $4.906B 23.72
DENTSPLY SIRONA (XRAY) United States $3.125B 9.33
CONMED (CNMD) United States $1.474B 11.03
STAAR Surgical (STAA) United States $0.860B 0.00
Lifevantage (LFVN) United States $0.163B 16.84
Pro-Dex (PDEX) United States $0.151B 16.50